Amneal Pharmaceuticals, Inc. (AMRX) DCF Valuation
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Amneal Pharmaceuticals, Inc. (AMRX) Bundle
Regardless of whether you're an investor or an analyst, this (AMRX) DCF Calculator is your go-to resource for accurate valuation. It comes preloaded with real data from Amneal Pharmaceuticals, Inc., allowing you to adjust forecasts and immediately observe the effects.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1,626.4 | 1,992.5 | 2,093.7 | 2,212.3 | 2,393.6 | 2,641.7 | 2,915.4 | 3,217.5 | 3,550.9 | 3,918.9 |
Revenue Growth, % | 0 | 22.51 | 5.08 | 5.67 | 8.2 | 10.36 | 10.36 | 10.36 | 10.36 | 10.36 |
EBITDA | 155.2 | 381.0 | 450.0 | 150.4 | 500.8 | 411.5 | 454.1 | 501.2 | 553.1 | 610.4 |
EBITDA, % | 9.54 | 19.12 | 21.49 | 6.8 | 20.92 | 15.58 | 15.58 | 15.58 | 15.58 | 15.58 |
Depreciation | 207.2 | 235.4 | 233.4 | 240.2 | 229.4 | 296.6 | 327.4 | 361.3 | 398.7 | 440.0 |
Depreciation, % | 12.74 | 11.81 | 11.15 | 10.86 | 9.58 | 11.23 | 11.23 | 11.23 | 11.23 | 11.23 |
EBIT | -52.0 | 145.7 | 216.6 | -89.8 | 271.4 | 114.8 | 126.7 | 139.9 | 154.4 | 170.4 |
EBIT, % | -3.2 | 7.31 | 10.35 | -4.06 | 11.34 | 4.35 | 4.35 | 4.35 | 4.35 | 4.35 |
Total Cash | 151.2 | 341.4 | 247.8 | 26.0 | 91.5 | 228.6 | 252.3 | 278.4 | 307.3 | 339.1 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | 635.9 | 674.2 | 662.6 | 741.8 | 613.7 | 865.2 | 954.8 | 1,053.8 | 1,163.0 | 1,283.5 |
Account Receivables, % | 39.1 | 33.84 | 31.65 | 33.53 | 25.64 | 32.75 | 32.75 | 32.75 | 32.75 | 32.75 |
Inventories | 381.1 | 490.6 | 489.4 | 530.7 | 581.4 | 632.5 | 698.0 | 770.3 | 850.2 | 938.3 |
Inventories, % | 23.43 | 24.62 | 23.37 | 23.99 | 24.29 | 23.94 | 23.94 | 23.94 | 23.94 | 23.94 |
Accounts Payable | 103.0 | 154.1 | 132.9 | 166.8 | 143.6 | 179.4 | 198.0 | 218.5 | 241.2 | 266.1 |
Accounts Payable, % | 6.33 | 7.74 | 6.35 | 7.54 | 6 | 6.79 | 6.79 | 6.79 | 6.79 | 6.79 |
Capital Expenditure | -97.4 | -66.2 | -52.6 | -90.6 | -69.2 | -99.4 | -109.7 | -121.1 | -133.6 | -147.4 |
Capital Expenditure, % | -5.99 | -3.32 | -2.51 | -4.1 | -2.89 | -3.76 | -3.76 | -3.76 | -3.76 | -3.76 |
Tax Rate, % | -108.57 | -108.57 | -108.57 | -108.57 | -108.57 | -108.57 | -108.57 | -108.57 | -108.57 | -108.57 |
EBITAT | -142.6 | -279.2 | 139.3 | -92.2 | 566.0 | 83.7 | 92.3 | 101.9 | 112.5 | 124.1 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -946.7 | -206.8 | 311.7 | -29.2 | 780.4 | 14.2 | 173.4 | 191.4 | 211.2 | 233.1 |
WACC, % | 8.44 | 3.34 | 6.62 | 8.44 | 8.44 | 7.05 | 7.05 | 7.05 | 7.05 | 7.05 |
PV UFCF | ||||||||||
SUM PV UFCF | 647.2 | |||||||||
Long Term Growth Rate, % | 4.00 | |||||||||
Free cash flow (T + 1) | 242 | |||||||||
Terminal Value | 7,940 | |||||||||
Present Terminal Value | 5,647 | |||||||||
Enterprise Value | 6,295 | |||||||||
Net Debt | 2,659 | |||||||||
Equity Value | 3,636 | |||||||||
Diluted Shares Outstanding, MM | 176 | |||||||||
Equity Value Per Share | 20.64 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real AMRX financials.
- Real-World Data: Historical data and forward-looking estimates (as highlighted in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe the effect of your inputs on Amneal Pharmaceuticals’ valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Customizable Financial Inputs: Adjust essential parameters such as revenue growth, EBITDA %, and capital expenditures tailored for Amneal Pharmaceuticals, Inc. (AMRX).
- Instant DCF Valuation: Quickly computes intrinsic value, NPV, and other financial metrics for informed decision-making.
- High-Precision Accuracy: Utilizes Amneal's actual financial data to deliver realistic valuation results.
- Simplified Scenario Analysis: Effortlessly evaluate various assumptions and analyze different outcomes.
- Efficiency Booster: Streamline your valuation process without the hassle of creating complex models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Amneal Pharmaceuticals’ pre-filled financial data and forecasts.
- Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust assumptions.
- Step 5: Evaluate the outputs and leverage the results for investment decisions.
Why Choose This Calculator for Amneal Pharmaceuticals, Inc. (AMRX)?
- Accurate Data: Utilize real Amneal financials for trustworthy valuation outcomes.
- Customizable: Tailor essential parameters like growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you the hassle of starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the pharmaceutical sector.
- User-Friendly: An intuitive design and clear instructions make it accessible for all users.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Amneal Pharmaceuticals stock (AMRX).
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for Amneal Pharmaceuticals (AMRX).
- Consultants: Deliver professional valuation insights related to Amneal Pharmaceuticals (AMRX) to clients quickly and accurately.
- Business Owners: Understand how pharmaceutical companies like Amneal Pharmaceuticals (AMRX) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios involving Amneal Pharmaceuticals (AMRX).
What the Template Contains
- Historical Data: Includes Amneal Pharmaceuticals’ past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Amneal Pharmaceuticals’ intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Amneal Pharmaceuticals’ financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.